Neurizon Therapeutics Limited has released a press release.
Last Patient Successfully Completes Treatment in OLE Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
- NUZ-001 Shows Positive Results in Human 3D Brain Model
- NUZ-001 shows promising respiratory outcome
- Neurizon Commences Initiatives to Lift Clinical Hold
- Appendix 4D - Half-year Financial Report - 31 December 2024
Later from Neurizon Therapeutics
- NUZ-001 Shows Promise in a Model of Huntington's Disease
- NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
- NUZ-001 Shows Significant Blood-Brain Barrier Penetration
- Neurizon develops liquid formulation of NUZ-001
- Neurizon Enters Global Licensing Agreement with Elanco
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics